Urovant Sciences Ltd.
UROV
UROV was delisted on the 26th of March, 2021.
21 hedge funds and large institutions have $66.8M invested in Urovant Sciences Ltd. in 2019 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 11 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
48% more capital invested
Capital invested by funds: $45.3M → $66.8M (+$21.5M)
19% less funds holding
Funds holding: 26 → 21 (-5)
45% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.88M |
| 2 |
PA
Perceptive Advisors
New York
|
+$2.46M |
| 3 |
Millennium Management
New York
|
+$1.4M |
| 4 |
PM
Prosight Management
Dallas,
Texas
|
+$1.02M |
| 5 |
BlackRock
New York
|
+$525K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
-$6.08M |
| 2 |
GTC
Ghost Tree Capital
New York
|
-$1.98M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.41M |
| 4 |
PWAM
Park West Asset Management
San Francisco,
California
|
-$436K |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$291K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LCM
26
Laurion Capital Management
New York
| – | -$173K | -26,205 | Closed |
|
27
Man Group
London,
United Kingdom
| – | -$128K | -19,369 | Closed |
|
28
Barclays
London,
United Kingdom
| – | -$37K | -5,627 | Closed |
|
29
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$22K | -3,390 | Closed |
|
|
PHK
30
Point72 Hong Kong
Hong Kong
| – | -$5K | -686 | Closed |
|
|
CSS
31
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$3K | -447 | Closed |
|
UROV Hedge Fund Activity: Q1 2019 in Review
21 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Urovant Sciences Ltd. (UROV) for Q1 2019, worth a combined $66.8M — up 48% from $45.3M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of UROV and 6 opened new positions — a net loss of 5 holders — while 4 trimmed existing stakes and 6 added.
The largest buyer was Fidelity Investments, adding an estimated $3.88M. The largest seller was Sio Capital Management, cutting an estimated $6.08M.
- 21 institutional investors held Urovant Sciences Ltd. (UROV) as of Q1 2019, down from 26 in Q4 2018.
- Funds reported $66.8M of Urovant Sciences Ltd. stock for Q1 2019, up 48% quarter-over-quarter.
- 6 funds opened new Urovant Sciences Ltd. positions in Q1 2019 and 11 closed out, a net change of -5 holders.
- The largest Urovant Sciences Ltd. buyer in Q1 2019 was Fidelity Investments, an estimated $3.88M added.
- The largest Urovant Sciences Ltd. seller in Q1 2019 was Sio Capital Management, an estimated $6.08M sold.
Based on aggregated 13F filings for Q1 2019.